targeted therapytyrosine kinaseTyrosine kinases (TKs) drive cell survival and proliferation in many normal and malignant cell types. TKs are frequently mutated in acute myeloid leukemia (AML) and hence are increasingly targeted. The management of AML has dra...
Acute Myeloid Leukemia (AML) is a bone marrow malignancy characterized by the infiltration of the bone marrow, blood and other tissues by clonal cells of the myeloid lineage with limited or no potential for differentiation [1]. From: Leukemia Research, 2022 ...
Therapy-related myelodysplasia and acute myeloid leukemiaSmita Bhatia, MD, MPH [Professor and Chair]Department of Population Sciences Ruth Ziegler Chair in Population Research City of HopeComprehensive Cancer Center Duarte, CAAbstractTherapy-related leukemia (t-MDS/AML) is a well known complication of...
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhi
LeukemiaMoore AS, Kearns PR, Knapper S, et al. Novel therapies for children with acute myeloid leukaemia. Leukemia. 2013;27:1451-1460.Moore AS, Kearns PR, Knapper S, Pearson AD, Zwaan CM. Novel therapies for children with acute myeloid leukaemia. Leukemia (2013) 27(7):1451-60. doi:...
Intensified Therapy for Acute Myeloid Leukemia.doi:10.1056/NEJM199410063311411Editorial. Comments on a report by Mayer, et al in the October 6, 1994 issue of 'The New England Journal of Medicine,' of a clinical trial that examined the effect of the dose of cytarabine given as post-remission ...
WHAT IS VYXEOS? VYXEOS is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)....
Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia Elisabete do Vale Campos, Ricardo Pinto, in Hematology, Transfusion and Cell Therapy, 2019 Introduction Acute myeloid leukemia (AML) is a hematopoietic neoplasm involving precursor cells committed to the mye...
Intermediate-risk acute myeloid leukemia therapy: current and future In recent years, research in molecular genetics has been instrumental in deciphering the molecular heterogeneity of acute myeloid leukemia (AML), in particular the subset of patients with "intermediate-risk" cytogenetics. However, at ...
Combination therapy of acute myeloid leukemia by dual PI3K/mTOR inhibitor BEZ235 and TLR-7/8 agonist R848 in murine model The applied combinational therapy with R848 and BEZ235 showed more effective results than the conventional chemotherapy in murine AML model of the current ... S Taghiloo,A...